Author of

• 17493

  +

  P2.02 - Poster Session with Presenters Present (ID 462)

  • Event: WCLC 2016
  • Type: Poster Presenters Present
  • Track: Locally Advanced NSCLC
  • Presentations: 1
  • Moderators:
  • Coordinates: 12/06/2016, 14:30 - 15:45, Hall B (Poster Area)

  • 17509

    +

    P2.02-016 - Real World Experience with Chemoradiotherapy in Locally Advanced NSCLC (ID 5175)

    14:30 - 14:30  |  Author(s): J. Lao
    • Abstract

    Background:
    Chemo-radiotherapy (CT-RT) remains the standard therapy for locally advanced Non-Small Cell Lung Cancer (LA NSCLC) . Concurrent therapy is the choice for fit patients, without a proven benefit of either induction or consolidation therapies. However, sometimes, as in our Health system, RT is not readily available from the beginning so CT is started upfront and RT started when possible.
    
    Methods:
    Charts from every patient treated with CT-RT in our Hospital between January/2008 and December/2015 for LA-NSCLC have been reviewed. Patient and therapy characteristics have been assessed.
    
    Results:
    184 patients (p) were found: Median age 64 years (41-84), male 151p (82,1%), PS 0/1/2: 34,2/63,6/1,6%. Histology: adenocarcinoma 34,8%, squamous carcinoma 51,8%, NOS 2,7%, NSCLC with neuroendocrine features 10,9%. Stage IIIa 32,1%, IIIb 67,9%. CT included a platinum salt in 98.9% of cases: cisplatin in 57,6% and carboplatin in 41.3%. Most frequent companion drugs were vinorelbine (35.9% overall, 55.7% within patients treated with cisplatin) and paclitaxel (38.0%, 77.6% of those combined with carboplatin). Median number of CT courses was 4 (1-5), and median course when RT was started was third (1-4). Median survival was 22.5 months (18.3-26.7). It was longer in squamous carcinomas (23.1m), male patients (23.3m), stage IIIa (27.5m) and cisplatin-treated (23.5m) although these differences were non-significant. The only significant factor for survival was PS (0= 33.2 m, 1= 19.0m, p<0.001). No differences in patient characteristics existed with respect to stage, gender or histologic subtype between cis- or carboplatin-treated patients. More patients with PS=0 were treated with cisplatin (49/63= 77%) and carboplatin was preferred for PS=1 patients (59/117= 50.4%, p<0.001).
    
    Conclusion:
    Despite our limitations to start RT early in the treatment of LA-NSCLC our results in real-world clinical practice were comparable to those reported in clinical trials. This was at the cost of increasing the burden of CT up to 4 courses. Probably, proper selection of patients was crucial, with PS 0 patients benefiting most from this approach. No major differences existed according the CT regimen administered (either the use of cis- or carboplatin as backbone or the partner drug used). In our experience, squamous carcinomas remained the most frequent subtype in LA_NSCLC.